California Approves Proposition 38 for Immunology Research Funding
California voters have successfully approved Proposition 38, enabling the state to issue $8.4 billion in bonds dedicated to advancing immunology and immunotherapy research aimed at combating chronic diseases.
According to reports from the Associated Press, the measure stipulates that at least $4.2 billion of the raised funds must be allocated specifically for research targeting cancers, heart disease, and Alzheimer’s disease. Furthermore, the state is authorized to form a partnership with a yet-to-be-named immunology and immunotherapy research institute, as designated by the California Department of Public Health. Half of the bond proceeds will be directed to this entity.
Critics of the proposition have raised concerns about the financial burden it places on taxpayers, suggesting that it could lead to decades of debt. They also highlighted that the stringent eligibility criteria for grants limit funding opportunities to a narrow range of candidates; notably, only the California Institute for Immunology and Immunotherapy currently aligns with these criteria. This institute was co-founded by Gary K. Michelson, a prominent philanthropist and the proposition’s principal advocate, who contributed $45 million to support the initiative.
The remaining bond funds will be allocated for competitive research grants in immunology and immunotherapy. A selection council, composed of representatives from various University of California campuses, colleges, and nonprofit research institutions, will be responsible for awarding these grants.
Supporters of Proposition 38 celebrated its passage, expressing relief amid federal funding cuts that have hindered clinical trials and delayed medical advancements across the country. Chris Tarver, president of the American Nurses Association of California, noted the significance of this victory for patients and their families, who have been striving for a breakthrough in their battles against life-altering diseases.
According to the Legislative Analyst’s Office, Californians can expect an annual repayment obligation ranging from $500 million to $600 million for approximately 20 years. Although there is potential for offsetting some of these costs through revenue generated from successful research, predicting which studies may yield viable marketable treatments remains uncertain.
Report compiled with contributions from Times staff writer Hannah Fry.
Discussion about this post